CARsgen Therapeutics Holdings Limited (SEHK: 2171)
Health Care · Biotechnology · CN
HK$11.63
-6.59% today · -36.1% 1Y
CARsgen Therapeutics Holdings Limited (SEHK: 2171) operates in the Biotechnology industry within the Health Care sector. The company is valued at $833.26M and employs 424 people.
Over the last twelve months the share price has lost 36.1%, trading between 10.87 and 28.60.
Tweenvest scores CARsgen Therapeutics Holdings Limited across four factors: quality 39/100, value 82/100. Its strongest factor is value.
2171 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $833.26M
- Revenue (TTM)
- $20.11M
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- HK$28.60
- 52-week low
- HK$10.87
- Avg volume (3M)
- —
- Shares outstanding
- 562.26M
- Employees
- 424
- Next earnings
- —
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
- ISIN
- KYG1996C1006
- Founded
- 2014
- Listed since
- Jun 18, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hangzhou Biotest Biotech Co.,Ltd.SHSE: 688767 | $865.08M | CN¥39.60 | -1.49% |
| Sana Biotechnology, Inc.NasdaqGS: SANA | $835.22M | $2.79 | 0.00% |
| Arbutus Biopharma CorporationNasdaqGS: ABUS | $834.92M | $4.22 | +0.96% |
| Oxford Biomedica plcLSE: OXB | $834.48M | £5.21 | -4.23% |
| ArriVent BioPharma, Inc.NasdaqGM: AVBP | $824.92M | $16.73 | -40.82% |
| Ardelyx, Inc.NasdaqGM: ARDX | $817.34M | $3.28 | +0.31% |
| Geron CorporationNasdaqGS: GERN | $787.03M | $1.23 | +0.41% |
| Immix Biopharma, Inc.NasdaqCM: IMMX | $784.26M | $9.46 | -2.27% |
Figures last refreshed Oct 11, 2026.